CMS
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
  • AI Discovery
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Sustainability
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardiovascular-Kidney-Metabolic and Gastroenterology
    • Skin Health Business
    • Ophthalmology
    • Southeast Asia & the Middle East Business
  • News
    • Company News
    • Partner News
    • Video News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Home
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Sustainability
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Skin Health Business
    • Ophthalmology
    • Southeast Asia & the Middle East Business
  • News
    • Company News
    • Partner News
  • Investors
    • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
×
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026
2026-07-02

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026

LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
2026-06-29

LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Next Day Disclosure Return
2026-06-24

Next Day Disclosure Return

Voluntary and Business Update Announcement New Drug Application of Class 1 Innovative Drug Recombinant Fully Human Bispecific Antibody Against Rabies Virus Silevimig Injection Approved in China
2026-06-22

Voluntary and Business Update Announcement New Drug Application of Class 1 Innovative Drug Recombinant Fully Human Bispecific Antibody Against Rabies Virus Silevimig Injection Approved in China

Next Day Disclosure Return
2026-06-17

Next Day Disclosure Return

Next Day Disclosure Return
2026-06-09

Next Day Disclosure Return

Next Day Disclosure Return
2026-06-08

Next Day Disclosure Return

Next Day Disclosure Return
2026-06-04

Next Day Disclosure Return

Next Day Disclosure Return
2026-06-03

Next Day Disclosure Return

Next Day Disclosure Return
2026-06-02

Next Day Disclosure Return

Next Day Disclosure Return
2026-06-01

Next Day Disclosure Return

  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Sustainability
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardiovascular-Kidney-Metabolic and Gastroenterology
    • Skin Health Business
    • Ophthalmology
    • Southeast Asia & the Middle East Business
  • News
    • Company News
    • Partner News
    • Video News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Privacy
  • Terms Of Use
All rights reserved by CMS Group 2001-2022 ERP of CMS Group
互联网药品信息服务备案凭证:(粤)-非经营性-粤网药信备字〔2026〕第00023号| 工业和信息化部备案管理系统网站 粤ICP备18157737号| 粤公网安备 44030502003605号